We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Chromosome Instability Patterns Predict Tumor Drug Response

By LabMedica International staff writers
Posted on 16 Jun 2022
Print article
Image: Computer-generated three dimensional drawing of a chromosome mutation (Photo courtesy of 123rf.com)
Image: Computer-generated three dimensional drawing of a chromosome mutation (Photo courtesy of 123rf.com)

By analyzing the differences in the number of repetitions of sequences of DNA within cancerous tumors, genomic researchers characterized 17 different types of chromosomal instability, which could be used to predict tumor drug response and to aid in the identifying future drug targets.

Chromosomal instability (CIN) is a type of genomic instability in which chromosomes are unstable, such that either whole chromosomes or parts of chromosomes are duplicated or deleted. Chromosomal instability is a common feature of cancer, occurring in around 80% of tumors, researchers are only now beginning to understand exactly what types or patterns of instability are present in any given tumor.

To increase this understanding, investigators at the University of Cambridge (United Kingdom) and colleagues at the Spanish National Cancer Research Center (Madrid, Spain) evaluated the extent, diversity, and origin of CIN across 7,880 tumors representing 33 cancer types.

Results of this evaluation revealed 17 different types of chromosomal instability. These chromosomal instability signatures could be used to predict how tumors might respond to drugs, as well as aiding in the identification of future drug targets.

Senior author Dr. Florian Markowetz, senior group leader at the Cancer Research UK Cambridge Institute of the University of Cambridge, said, "The more complex the genetic changes that underlie a cancer, the more difficult they are to interpret and the more challenging it is to treat the tumor. This is tragically clear from the very low survival rates for cancers that arise as a result of chromosomal instability. Our discovery offers hope that we can turn things around, providing much more sophisticated and accurate treatments. We are now working hard to bring our technology to patients and develop it to a level where it can transform patients' lives."

The CIN study was published in the June 15, 2022, online edition of the journal Nature.

Related Links:
University of Cambridge 
Spanish National Cancer Research Center 

 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.